Time to Surgery Does Not Inuence Survival Outcome in Patients With Upfront Resected Pancreatic Adenocarcinoma

This study evaluated the impact of time to surgery (TTS) on overall survival (OS), disease free survival (DFS) and postoperative complication rate in patients with upfront resected pancreatic adenocarcinoma (PA). Methods We retrospectively included patients who underwent upfront surgery for PA between January 1, 2004 and December 31, 2014 from four French centers. TTS was dened as the number of days between the date of the rst consultation in specialist care and the date of surgery. DFS for a 14-day TTS was the primary endpoint. We also analyzed survival depending on different delay cut-offs (7, 14, 28, 60 and 75 days). Results A total of 168 patients were included. 59 patients (35%) underwent an upfront surgery within 14 days. Patients in the higher delay group had signicantly more vein resections and endoscopic biliary drainage. Adjusted OS (p = 0.44), DFS (p = 0.99), stulas (p = 0.41), hemorrhage (p = 0.59) and severe post-operative complications (p = 0.82) were similar in both groups. Other delay cut-offs had no impact on OS or DFS. TTS seems to have no impact on OS, DFS and 90-day postoperative morbidity.


Introduction
Pancreatic adenocarcinoma (PA) is one of the most aggressive digestive cancers. Five-year overall survival (OS) rate is estimated below 8% (all stages combined) (1). This malignancy is expected to be the second leading cause of cancer-related death in Europe by 2030 (2).
Actual standard of care for resectable PA is upfront carcinologic surgery followed by adjuvant chemotherapy (3). Unfortunately, prognosis remains poor despite improvements in surgical technique, perioperative care, diagnosis accuracy, patient selection and more active chemotherapy regimen (4). New perspectives are needed to increase both survival rates and quality of life for patients diagnosed with PA.
One of the objectives studied in other cancers has been to reduce time to treatment by improving the organization of the care pathway. Time to surgery (TTS) has turned out to be a major prognostic factor associated with survival in several malignancies (5)(6)(7)(8). To date, the impact of TTS on OS and disease-free survival (DFS) in patients diagnosed with resectable PA remains unclear (9).
Moreover, pancreatic resection is one of the most challenging surgery, with signi cant postoperative morbidity and mortality (10). Improving preoperative status ─ by means of biliary drainage, hemostasis correction, prehabilitation with nutritional and adapted physical activity interventions (11) ─ is needed before surgery as complications are more frequent in un t patients (12). Shorter TTS may not allow to optimize prehabilitation but could improve carcinologic prognosis.
This study evaluated the impact of TTS on OS, DFS and postoperative complication rate in patients who underwent upfront curative intent surgical resection of a PA.

Material And Methods
We retrospectively included patients with upfront resected PA between January 1, 2004 and December 31, 2014 in three tertiary French centers (Reims University Hospital, Amiens University Hospital, Strasbourg University Hospital) and in one private center (Reims Courlancy Clinic). Patients were screened with administrative coding and multidisciplinary tumor board meetings data (MTBM). All MTBM applied the consensus of the International Study Group of Pancreatic Surgery requiring the expertise of a senior radiologist and a pancreatic surgeon (13).
All patients who underwent upfront curative intent resection for a PA were included. Patients were excluded in case of neoadjuvant treatment or incomplete surgical resection (R2).
Basic baseline clinical, biological (i.e. ECOG performance status (PS), initial symptoms, tumor location, preoperative biliary drainage, bilirubin levels and neutrophil-lymphocyte ratio), pathological and surgical data (i.e. TNM staging, lymph node ratio [number of invaded lymph nodes/total number of resected lymph nodes], resection margins [R0 or R1], venous and adjacent organ involvement [gastric, colon or left adrenal resection]), were collected using medical records. Follow up characteristics such as postoperative complications, adjuvant treatment regimen and evolution of the disease (tumor recurrence, site of recurrence and death) were also collected.
Time to decision (TTD) was de ned as the delay in days between rst specialized medical interview (gastroenterologist, pancreatic surgeon, or medical oncologist) and MTBM decision. Time to surgery (TTS) was de ned as the delay between the rst specialized medical interview (gastroenterologist, pancreatic surgeon, medical oncologist) and surgery. The 90-day postoperative complications were assessed using Dindo-Clavien classi cation (14). Grade III or higher grade complications were considered as severe (14). Follow-up was standard and left to the physician's discretion according to guidelines prevailing at the time of the treatment(3). The primary objective was to determine the impact of a shorter (≤ 14 days) TTS in DFS improvement. This threshold was chosen in accordance with literature review and the investigators' experience (15)(16)(17)(18)(19)(20). Secondary objectives were to evaluate OS and DFS according to other TTS and TTD thresholds (7-, 14-, 28-, 60-and 75-day delay). Ninety-day morbidity rate was compared using a 14-day delay. Endpoint date was set to provide at least a 12-month follow-up (December 31, 2015).

Statistical analysis
Continuous variables were described as median and interquartile ranges. Categorical variables were described as frequencies expressed with percentages. Groups with different management delays were compared using Mann-Whitney test (non-normal continuous variables) and Chi square test or Fisher test (categorical variables), depending on variable type and sample size. OS was calculated from date of surgery procedure to date of death or censoring at the date of last visit. DFS was calculated from the date of the surgical procedure to the date of progression, death or censoring at the date of last visit (9). Survival curves were established using the Kaplan-Meier method and compared using Cox proportional-hazards model for univariate and multivariate analyses. We pre-planned several survival analyses strati ed on different delay cut-offs (7, 14, 28, 60 and 75 days). Complication rates were analyzed according to a 14-day delay using Mann-Whitney test and logistic regression adjusted for factors with a p < 0.2 in stepwise regression. All data analyses were performed using R (R Development Core Team, 2005). Statistical signi cance was de ned as a p value < 0.05 for all tests.

Ethics
Patient's records were anonymized prior to analysis. Database was constituted in accordance with the reference methodology MR004 of the National Commission of Liberties and Informatics. (n°2206749, 13/09/2018). As per French regulations, no additional ethical review was required.

Results
Population characteristics at baseline A total of 534 patients with a PA were screened. Among them, 201 patients underwent an upfront surgery procedure with curative intent; 33 were nally excluded due to unresectable tumor upon surgical reassessment (27) or insu cient data collection (6).The study owchart is presented in Fig. 1 (Flowchart).
Patient characteristics are presented in Table 1. Most patients were men (57.7%), with a median age of 66 years (IQR :58-71). ECOG PS was available in 60.2% of the cases. Only four patients were ECOG PS > 1. Jaundice was the main symptom (69%) at rst patient visit, and diagnosis was made during a hospital stay in 44.6% of the cases. Tumors were mainly located in the head of the pancreas (79.8%), warranting a biliary drainage in 64 patients (38.1%). Median total bilirubin prior to any biliary drainage was 197.5µmol/L (IQR :135.5-336.75). Patient characteristics strati ed upon TTS inferior to 14 days are presented in Table 2. A total of 59 patients (35%) had their tumor resected less than 14 days after rst consultation. Patients in the longer delay group had more frequent vein resections, endoscopic biliary drainage (p < 0.001), jaundice (p = 0.044), and higher median total serum bilirubin levels (p < 0.001).  (Table 3). TTD did not impact either DFS or OS, regardless of the delay cut-off (Table 3). Footnotes : vs :versus ; OR :odds ratio ; CI 95% :con dence interval 95% ; * Adjusted analysis for vein resection, jaundice, and hemorrhage Adjusted OS (on organ and vein invasion, severe complications, and adjuvant chemotherapy) and adjusted DFS (on vein invasion, organ resection, severe complications, R status, N status, and adjuvant chemotherapy) were not signi cantly improved with a shorter TTS, inferior or equal to 14 days (p = 0.44 (Table 3).

Discussion
In our study, TTS had no impact on DFS and OS in patients with upfront resected PA. Similar rates of hemorrhage, stula, or severe post-operative complications were observed regardless of TTS. This is the rst study to evaluate the impact of TTS on the 90-day morbidity.
Shortening time to treatment has been a promising approach to improve survival. TTS has been set as a quality care index in other malignancies (6,7,21,22). As an example, HCC radiofrequency ablations warrant an under ve-week management delay to avoid any impact on prognosis(6).
In PA, TTS impact remains unclear. Our results are consistent with most of the previous cohorts that showed no signi cant in uence of TTS on survival rate for patients undergoing a curative intent resection for PA (15,17,23). Eshuis et al. concluded that biliary drainage and prolonged TTS do not impair survival rates in a randomized controlled trial (24). On the contrary, Swords et al. showed a modestly improved OS (1.8 months) and a higher 30 and 90-day post-operative mortality in shorter TTS, but at the cost of including a large number of patients (25). Subgroup analysis suggested that shorter TTS could improve resecability rate and prognosis in small tumors (15,25,26). Finally, none of these studies analyzed the consequences of shorter TTS on postoperative complications such as hemorrhage, stulas or Dindo-Clavien classi cation.
Published studies, including ours, have failed to demonstrate a signi cant survival bene t with shorter delays before upfront surgery in PA. However, PA arises from pancreatic parenchyma decades before being symptomatic and diagnosed, suggesting slow growth at early stages (27). There is also evidence to support the rapid growth of PA, in later natural history once diagnosed, with an estimated time to progression from a T1 to a T4 stage of approximately 14 months(28). Tumor volume growth could thereby be considered as a factor distinct from the disease stage. Marchegiani et al. showed a TTS effect on survival for smaller tumors (T1 and T2)(26). Shorter TTS could impact resecability and disease-free survival in this speci c patient subgroup. In our study, only 28 patients (16.7%) had a T1 or T2 disease stage, making subgroup analyses futile.
Nevertheless, median TTS seems to be increasing year after year due to the incremental PA incidence and the frequent referral to expert centers (21). As TTS has no or little impact on prognosis, management strategy could be modi ed to allow su cient time to con rm diagnosis in ambivalent cases and integrate preoperative chemotherapy and prehabilitation strategy. A 28-day minimum delay between last liver imaging and surgery remains well established to avoid any curative surgery performed on patients with liver metastases(3).
No link was observed for stula, hemorrhage, or severe post-operative complications when TTS was shortened. Post pancreatectomy hemorrhage is mainly due to anastomotic leaks causing pseudoaneurysms (29). Also, when performed early, these interventions are less likely to be the subject of technical debate in multidisciplinary surgical meetings and patients may be less well prepared (uncorrected coagulation, nutritional status, or jaundice). Moreover, signi cantly higher median bilirubin in the shorter delay group can lead to troubled hemostasis, facilitating post-operative hemorrhage (30).
Our study has several limitations. First, patients with macroscopically incomplete resection (R2) or those who nally did not undergo a curative surgery, despite an initially resectable primary tumor, were not included. These patients could potentially have longer delays explaining tumor progression. Unfortunately, they were not considered in our analysis avoiding performing an intention-to-treat analysis. Furthermore, patients who waited longer without any treatment but nally underwent a curative surgical procedure may have had slower-progressive disease with a better prognosis. Preselecting candidates for curative surgery on their time to progression in the setting of such an aggressive disease seems unethical. Also, 116 patients (69%) were diagnosed upon jaundice presentation, while only 64 (38.1%) experienced a radiological or endoscopic biliary drainage. Patients treated before 2010 were more frequently resected with higher bilirubin levels. Moreover, the power of the study could be insu cient due to the limited number of inclusion centers and retrospectively included patients. Finally, three of the four inclusion centers, including 92.9% of the patients, were tertiary hospitals. We cannot exclude a selection bias and a confusion effect due to highly skilled techniques developed in these centers with low complication rates.
Surgery remains the only existing treatment to cure PA(3). Recent progress with polychemotherapy regimens and better patient selection for surgery has modestly improved overall survival (31,32). Moreover, new management strategies including neoadjuvant and induction chemotherapies are to be interpreted differently from passive delay where no therapeutic interventions occur. New perspectives must be found to increase the survival and quality of life of these patients. PA may not be the most suitable malignancy to study TTS as a quality metric(33). However, the COVID-19 pandemic has called for urgent case hierarchization and has thereby raised new questions about carcinologic surgical priorities. Ongoing multicentric CAPANCOVID-19 (https://clinicaltrials.gov/ct2/show/NCT04406571) tries to measure the impact of the COVID-19 pandemic causing prolonged management delay, from surgery to palliative situations.
We showed that TTS seems to have no impact on OS, DFS and 90-day postoperative morbidity. Other trials need to be carried out to understand the role of TTS in smaller tumor sizes. Figure 1 Flowchart n :total population ; R :resection status